<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

The Cancer Letter

Femara Better Suppressor Of Estrogen, Study Finds

February 22, 2002

Sen. Feinstein To Introduce New National Cancer Act.

February 22, 2002

Recombinant Protein C Cuts Risk Of Sepsis Death

February 22, 2002

ImClone Offered C225 Deal To Seven Firms Prior To BMS.

February 22, 2002

Antidepressant Provides Cool Choice For Hot Flashes

February 22, 2002

NIH Panel Outlines Strategies To Manage Adrenal Tumors.

February 22, 2002

Increased Lung Cancer Risk After Hodgkin’s Treatment

February 22, 2002

Clinical Trials Approved By NCI Last Month Listed

February 22, 2002

Expert Review Of ImClone Protocol Concludes C225 Approval Unlikely.

February 15, 2002

Retrospective Data Clean-Up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”.

February 15, 2002